Literature DB >> 33580123

Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.

Zaeema Naveed1, Howard S Fox2, Christopher S Wichman3, Morshed Alam3, Pamela May2, Christine M Arcari1, Jane Meza3, Steven Totusek2, Lorena Baccaglini4.   

Abstract

HIV-related neurocognitive impairment (NCI) may increase the risk of death. However, a survival disadvantage for patients with NCI has not been well studied in the post-combination antiretroviral therapy (cART) era. Specifically, limited research has been conducted considering the reversible nature and variable progression of the impairment and this area demands further evaluation. We performed multivariable Cox proportional hazards modeling to assess the association between baseline NCI (global T scores) and mortality. A joint modeling approach was then used to model the trajectory of global neurocognitive functioning over time and the association between neurocognitive trajectory and mortality. Among the National NeuroAIDS Tissue Consortium's (NNTC) HIV-infected participants, we found a strong negative association between NCI and mortality in the older age groups (e.g., at age = 55, HR = 0.79; 95% CI 0.64-0.99). Three neurocognitive sub-domains (abstraction and executive functioning, speed of information processing, and motor) had the strongest negative association with mortality. Joint modelling indicated a 33% lower hazard for every 10-unit increase in global T scores (HR = 0.67; 95% CI 0.56-0.80). The study identified older HIV-infected individuals with NCI as a group needing special attention for the longevity of life. The study has considerable prognostic utility by not only predicting mortality hazard, but also future cognitive status.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33580123      PMCID: PMC7881128          DOI: 10.1038/s41598-021-83131-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

1.  Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study.

Authors:  François-Xavier Lescure; Lars Haukali Omland; Frederik Neess Engsig; Casper Roed; Jan Gerstoft; Gilles Pialoux; Gitte Kronborg; Carsten Schade Larsen; Niels Obel
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

2.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Authors:  Judith S Currier; Jens D Lundgren; Andrew Carr; Daniel Klein; Caroline A Sabin; Paul E Sax; Jeffrey T Schouten; Marek Smieja
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

3.  Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  J Neurovirol       Date:  2011-03-17       Impact factor: 2.643

Review 4.  Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Belinda Cruse; Lucette A Cysique; Romesh Markus; Bruce J Brew
Journal:  J Neurovirol       Date:  2012-04-14       Impact factor: 2.643

Review 5.  Neurologic complications of HIV disease and their treatment.

Authors:  Scott L Letendre; Ronald J Ellis; Beau M Ances; J Allen McCutchan
Journal:  Top HIV Med       Date:  2010 Apr-May

Review 6.  HIV dementia: an evolving disease.

Authors:  Justin C McArthur
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

7.  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Authors:  Krishnan Bhaskaran; Osamah Hamouda; Mette Sannes; Faroudy Boufassa; Anne M Johnson; Paul C Lambert; Kholoud Porter
Journal:  JAMA       Date:  2008-07-02       Impact factor: 56.272

Review 8.  HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.

Authors:  Kathryn A Lindl; David R Marks; Dennis L Kolson; Kelly L Jordan-Sciutto
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-16       Impact factor: 4.147

Review 9.  Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection.

Authors:  Edana Cassol; Vikas Misra; Susan Morgello; Dana Gabuzda
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-21       Impact factor: 4.147

10.  Diagnostic accuracy of the International HIV Dementia Scale and HIV Dementia Scale: A meta-analysis.

Authors:  Xueying Hu; Yang Zhou; Jianxiong Long; Qiming Feng; Rensheng Wang; Li Su; Tingting Zhao; Bo Wei
Journal:  Exp Ther Med       Date:  2012-08-14       Impact factor: 2.447

View more
  3 in total

1.  Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV.

Authors:  Mattia Trunfio; Davide De Francesco; Daniela Vai; Caterina Medina; Maurizio Milesi; Simone Domini; Chiara Alcantarini; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  AIDS Behav       Date:  2022-01-04

2.  Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years.

Authors:  Bin Tang; A C Collier; S Morgello; D Cookson; N Sacktor; Ronald J Ellis; Christina M Marra; David B Clifford; Benjamin B Gelman; Jessica Robinson-Papp; J Allen McCutchan; Scott Letendre; Robert K Heaton; Igor Grant
Journal:  Brain Behav Immun Health       Date:  2022-03-10

3.  Identification of Youthful Neurocognitive Trajectories in Adults Aging with HIV: A Latent Growth Mixture Model.

Authors:  Rowan Saloner; Judith D Lobo; Emily W Paolillo; Laura M Campbell; Scott L Letendre; Mariana Cherner; Igor Grant; Robert K Heaton; Ronald J Ellis; Scott C Roesch; David J Moore
Journal:  AIDS Behav       Date:  2021-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.